Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boyle

Showing results (1171-1180 of 1,217) with videos related to

Pageof 122
Sort By:
Nature Communications|June 15, 2022
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomesMark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|January 26, 2019
Cyclooctatetraene: A Bioactive Cubane Paradigm ComplementHui Xing, Sevan D Houston, Xuejie Chen, et al.
Nature Communications|February 5, 2026
Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myelomaKane A Foster, Elise Rees, Louise Ainley, et al.
Blood|March 9, 2017
Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stressWei Shi, Therese Vu, Didier Boucher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaEileen M Boyle, Cody Ashby, Ruslana G Tytarenko, et al.
JAMA Oncology|June 25, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe TrialPaolo Tarantino, Tianyu Li, Esther Ritah Ogayo, et al.
Inflammatory Bowel Diseases|May 17, 2019
Challenges in IBD Research: Pragmatic Clinical ResearchFrank I Scott, David T Rubin, Subra Kugathasan, et al.
Angewandte Chemie (International Ed. in English)|February 6, 2016
Validating Eaton's Hypothesis: Cubane as a Benzene BioisostereBenjamin A Chalmers, Hui Xing, Sevan Houston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaBrian A Walker, Eileen M Boyle, Christopher P Wardell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31Karen A Gelmon, Frances M Boyle, Bella Kaufman, et al.
Pageof 122

Showing results (1171-1180 of 1,217) with videos related to

Sort By:
Pageof 122
Nature Communications|June 15, 2022
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomesMark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|January 26, 2019
Cyclooctatetraene: A Bioactive Cubane Paradigm ComplementHui Xing, Sevan D Houston, Xuejie Chen, et al.
Nature Communications|February 5, 2026
Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myelomaKane A Foster, Elise Rees, Louise Ainley, et al.
Blood|March 9, 2017
Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stressWei Shi, Therese Vu, Didier Boucher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaEileen M Boyle, Cody Ashby, Ruslana G Tytarenko, et al.
JAMA Oncology|June 25, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe TrialPaolo Tarantino, Tianyu Li, Esther Ritah Ogayo, et al.
Inflammatory Bowel Diseases|May 17, 2019
Challenges in IBD Research: Pragmatic Clinical ResearchFrank I Scott, David T Rubin, Subra Kugathasan, et al.
Angewandte Chemie (International Ed. in English)|February 6, 2016
Validating Eaton's Hypothesis: Cubane as a Benzene BioisostereBenjamin A Chalmers, Hui Xing, Sevan Houston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed MyelomaBrian A Walker, Eileen M Boyle, Christopher P Wardell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31Karen A Gelmon, Frances M Boyle, Bella Kaufman, et al.
Pageof 122